

10/718,077

DUE TO FILE SIZE AND SCORE LIMITATIONS, SEARCH REQUEST FORM IS SUBMITTED TO SCORE SEPARATELY

INVENTOR SEARCH


=> d ibib abs hitstr l6 1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:934322 HCAPLUS Full-text
DOCUMENT NUMBER: 141:400911
TITLE: Particle-forming compositions containing fused
pyrrolocarbazoles
INVENTOR(S): Dickason, Dave; McIntyre, Bradley T.
; Patel, Piyush R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.
Ser. No. 698,901.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040220176	A1	20041104	US 2003-718077	20031120
US 6200968	B1	20010313	US 1999-368409	19990805
US 6660729	B1	20031209	US 2000-698901	20001027
AU 2004292524	A1	20050609	AU 2004-292524	20041112
CA 2545545	A1	20050609	CA 2004-2545545	20041112
WO 2005051958	A2	20050609	WO 2004-US37928	20041112
WO 2005051958	A3	20060112		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1685137	A2	20060802	EP 2004-810908	20041112
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU			
CN 1882594	A	20061220	CN 2004-80034403	20041112
BR 2004016733	A	20070116	BR 2004-16733	20041112
JP 2007512333	T	20070517	JP 2006-541280	20041112
MX 2006PA05714	A	20060817	MX 2006-PA5714	20060519
KR 2007006674	A	20070111	KR 2006-709805	20060519
NO 2006002381	A	20060609	NO 2006-2381	20060524
IN 2006KN01583	A	20070504	IN 2006-KN1583	20060608
PRIORITY APPLN. INFO.:			US 1998-95611P	P 19980806
			US 1999-368409	A3 19990805
			US 2000-698901	A2 20001027
			US 2003-718077	A 20031120

OTHER SOURCE(S):
GI

MARPAT 141:400911



I

AB A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compds. Formulations were prepared containing I, PEG, and Poloxamer 188.

IT 9002-96-4, TPGS 9004-99-3, Myrj 52 25322-68-3,
Peg 106392-12-5, Poloxamer 188 222414-51-9,
Polyethylene glycol hydroxystearate


RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)

(particle-forming compns. containing fused pyrrolocarbazoles)


RN 9002-96-4 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -[4-[[(2R)-3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-yl]oxy]-1,4-dioxobutyl]- ω -hydroxy- (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 9004-99-3 HCAPLUS


10/718,077

CN Poly(oxy-1,2-ethanediyl), α -(1-oxooctadecyl)- ω -hydroxy- (CA INDEX NAME)



RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




RN 106392-12-5 HCAPLUS

CN Oxirane, 2-methyl-, polymer with oxirane, block (CA INDEX NAME)

CM 1

CRN 75-56-9

CMF C3 H6 O



CM 2


CRN 75-21-8

CMF C2 H4 O




RN 222414-51-9 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -(hydroxy-1-oxooctadecyl)- ω -hydroxy- (CA INDEX NAME)




D1-OH

IT 263554-49-0 329684-15-3
 RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particle-forming compns. containing fused pyrrolocarbazoles)
 RN 263554-49-0 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 329684-15-3 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)



IT 258342-87-9 329684-08-4
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particle-forming compns. containing fused pyrrolocarbazoles)
 RN 258342-87-9 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,


10/718,077

5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 329684-08-4 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl- (9CI) (CA INDEX NAME)




10/718,077

DISPLAY OF REQUESTED COMPOUND

=> d 110

L10 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 329684-15-3 REGISTRY
ED Entered STN: 02 Apr 2001
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)
MF C26 H21 N3 O4
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


4 REFERENCES IN FILE CA (1907 TO DATE)

4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 02 Apr 2001

RESULTS FROM REGISTRY, CAPLUS, AND USPATFULL

```
=> d que stat l17
L7          STR
```



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 33

STEREO ATTRIBUTES: NONE

```
L9          699 SEA FILE=REGISTRY SSS FUL L7
L11         660 SEA FILE=HCAPLUS ABB=ON  L9
L12         1 SEA FILE=REGISTRY ABB=ON  "POLYOXYL STEARATE"/CN
L13         1 SEA FILE=REGISTRY ABB=ON  "POLYETHYLENE GLYCOL"/CN
L14         12 SEA FILE=HCAPLUS ABB=ON  L11 AND (L12 OR ?POLYOXYL?(W)?STEARATE
          ? OR L13 OR ?POLYETHYLENE?(W)?GLYCOL?)
L15         5 SEA FILE=HCAPLUS ABB=ON  L14 AND (PRD<19990508 OR PD<19990508)
L16         24 SEA FILE=USPATFULL ABB=ON  L14 AND (PRD<19990508 OR PD<19990508
          )
L17         27 DUP REMOV L15 L16 (2 DUPLICATES REMOVED)
```

```
=> d ibib abs hitstr l17 1-27
```

```
L17  ANSWER 1 OF 27  USPATFULL on STN
ACCESSION NUMBER:    2007:231812  USPATFULL  Full-text
TITLE:              Detection and modulation of IAPs and NAIP for the
                    diagnosis and treatment of proliferative disease
INVENTOR(S):        Korneluk, Robert G., Ottawa, CANADA
                    MacKenzie, Alexander E., Ottawa, CANADA
                    Liston, Peter, Ottawa, CANADA
                    Baird, Stephen, Ottawa, CANADA
                    Tsang, Benjamin K., Nepean, CANADA
                    Pratt, Christine, Nepean, CANADA
```

NUMBER	KIND	DATE
-----	-----	-----

10/718,077

PATENT INFORMATION: US 20070203088 A1 20070830
APPLICATION INFO.: US 2006-509784 A1 20060825 (11)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2006-385739, filed on 22
Mar 2006, PENDING Continuation of Ser. No. US
2001-974592, filed on 9 Oct 2001, GRANTED, Pat. No. US
7087584 Continuation of Ser. No. US 2000-617053, filed
on 14 Jul 2000, GRANTED, Pat. No. US 6300492
Continuation of Ser. No. US 1997-800929, filed on 13
Feb 1997, GRANTED, Pat. No. US 6133437

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-30590P	19961114 (60)	<--
	US 1996-17354P	19960426 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PHILIP SWAIN, PHD, C/O GOWLING LAFLEUR HENDERSON, 1 PLACE VILLE MARIE,, 37TH FLOOR, MONTREAL, QC, H3B 3P4, CA		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	33 Drawing Page(s)		
LINE COUNT:	2973		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9, K252a

(NAIP (neuronal apoptotic inhibitory protein) and IAP polypeptides for neuronal disease treatment and prevention, and drug screening methods)

RN 99533-80-9 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester,
(9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




L17 ANSWER 2 OF 27 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1
 ACCESSION NUMBER: 2004:934322 HCAPLUS Full-text
 DOCUMENT NUMBER: 141:400911
 TITLE: Particle-forming compositions containing fused
 pyrrolocarbazoles
 INVENTOR(S): Dickason, Dave; McIntyre, Bradley T.; Patel, Piyush R.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S.
 Ser. No. 698,901.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040220176	A1	20041104	US 2003-718077	20031120 <--
US 6200968	B1	20010313	US 1999-368409	19990805
US 6660729	B1	20031209	US 2000-698901	20001027 <--
AU 2004292524	A1	20050609	AU 2004-292524	20041112
CA 2545545	A1	20050609	CA 2004-2545545	20041112
WO 2005051958	A2	20050609	WO 2004-US37928	20041112
WO 2005051958	A3	20060112		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1685137	A2	20060802	EP 2004-810908	20041112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
CN 1882594	A	20061220	CN 2004-80034403	20041112
BR 2004016733	A	20070116	BR 2004-16733	20041112
JP 2007512333	T	20070517	JP 2006-541280	20041112
MX 2006PA05714	A	20060817	MX 2006-PA5714	20060519
KR 2007006674	A	20070111	KR 2006-709805	20060519
NO 2006002381	A	20060609	NO 2006-2381	20060524
IN 2006KN01583	A	20070504	IN 2006-KN1583	20060608
PRIORITY APPLN. INFO.:				
			US 1998-95611P	P 19980806 <--
			US 1999-368409	A3 19990805
			US 2000-698901	A2 20001027
			US 2003-718077	A 20031120
			WO 2004-US37928	W 20041112
OTHER SOURCE(S): MARPAT 141:400911				
GI				



- AB A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compds. Formulations were prepared containing I, PEG, and Poloxamer 188.
- IT 9004-99-3, Myrj 52 25322-68-3, Peg
 RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particle-forming compns. containing fused pyrrolocarbazoles)
- RN 9004-99-3 HCAPLUS
- CN Poly(oxy-1,2-ethanediyl), α -(1-oxooctadecyl)- ω -hydroxy- (CA INDEX NAME)




- RN 25322-68-3 HCAPLUS
- CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




- IT 263554-49-0 329684-15-3
 RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particle-forming compns. containing fused pyrrolocarbazoles)
- RN 263554-49-0 HCAPLUS
- CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077



RN 329684-15-3 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)




IT 258342-87-9 329684-08-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particle-forming compns. containing fused pyrrolocarbazoles)


RN 258342-87-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 329684-08-4 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl- (9CI) (CA INDEX NAME)



L17 ANSWER 3 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2004:165980 USPATFULL [Full-text](#)

TITLE: Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist

INVENTOR(S): Masferrer, Jaime, Ballwin, MO, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation, St. Louis, MO, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040127470	A1	20040701
APPLICATION INFO.:	US 2003-651916	A1	20030829 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-470951, filed on 22 Dec 1999, ABANDONED		

10/718,077

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-113786P	19981223 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Charles E. Dunlap, Nelson Mullins Riley & Scarborough, LLP, P.O. Box 11070, Columbia, SC, 29211-1070		
NUMBER OF CLAIMS:	34		
EXEMPLARY CLAIM:	1		
LINE COUNT:	8937		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 156177-59-2, CEP-751 183488-70-2, CEP-2563
(as EGFR antagonist; COX-2 inhibitor in combination with epidermal growth factor receptor antagonist for prevention or treatment of neoplasia)

RN 156177-59-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-70-2 USPATFULL

CN β -Alanine, L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HC1

L17 ANSWER 4 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:86849 USPATFULL Full-text

TITLE: Cellular proteins as targets for the treatment of pathogens resistant to drugs that target pathogen-encoded proteins

INVENTOR(S): Schaffer, Priscilla A., Boston, MA, UNITED STATES
Schang, Luis M., Edmonton, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030060457	A1	20030327
APPLICATION INFO.:	US 2000-905695	A1	20001206 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2000-951058, filed on 12 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-656592, filed on 7 Sep 2000, PENDING Continuation of Ser. No. WO 1999-US16252, filed on 16 Jul 1999, PENDING		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-94805P	19980731 (60)	<--
	US 1999-131264P	19990427 (60)	<--
	US 1999-140926P	19990624 (60)	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN, LEWIS & BOCKIUS LLP, 1701 MARKET STREET, PHILADELPHIA, PA, 19103-2921

NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 38 Drawing Page(s)
LINE COUNT: 3979
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

10/718,077

AB The invention relates to the identification of cdk inhibitors as inhibitors of gene expression, replication and reactivation in pathogenic agents. Compositions and assays for the identification and use of such inhibitors are provided, as are methods of use of the inhibitors

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9, K252a

(cellular proteins as targets for treatment of pathogens resistant to drugs targeting pathogen-encoded proteins, and use of cdk inhibitors)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L17 ANSWER 5 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:17947 USPATFULL Full-text
TITLE: Agent for treating ophthalmopathy
INVENTOR(S): Nakata, Katsuhiko, Sakurai-shi, JAPAN
Kageyama, Masaaki, Osaka, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030013701	A1	20030116
APPLICATION INFO.:	US 2002-228645	A1	20020826 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-807293, filed on 11 Jun 2001, GRANTED, Pat. No. US 6451787 A 371 of International Ser. No. WO 1999-JP5605, filed on 12 Oct 1999, UNKNOWN		

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1998-290194	19981013	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103		
NUMBER OF CLAIMS:	5		

10/718,077

EXEMPLARY CLAIM: 1

LINE COUNT: 349

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Use of the compound represented by general formula (I) for remedies of and protection against eye diseases is disclosed. General formula (I): ##STR1##

(wherein, R.sup.1 and R.sup.2 independently represent a lower alkyl group, R.sup.3 and R.sup.4 independently represent a hydrogen atom or a lower alkyl group)

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 156177-65-0 263554-49-0

(remedy for ocular diseases)

RN 156177-65-0 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 263554-49-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 6 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2003:321517 USPATFULL Full-text

TITLE: Particle-forming compositions containing fused pyrrolocarbazoles

INVENTOR(S): Dickason, David A., Cincinnati, OH, United States
 Patel, Piyush R., Wallingford, PA, United States
 Corvari, Vincent, Nashua, NH, United States
 Shek, Efraim, Wynnewood, PA, United States
 Herman, Joseph L., West Chester, PA, United States
 Skell, Jeffry M., Rahway, NJ, United States
 PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6660729	B1	20031209
APPLICATION INFO.:	US 2000-698901		20001027 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-368409, filed on 5 Aug 1999, now patented, Pat. No. US 6200968		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-95611P	19980806 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Criares, Theodore J.		
LEGAL REPRESENTATIVE:	Hrubiec, Robert T., Voelk, Eric K.		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	1461		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 258342-87-9 258342-88-0 258342-89-1

10/718,077

(particle-forming compns. containing fused pyrrolocarbazoles)


RN 258342-87-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 258342-88-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)




RN 258342-89-1 USPTAFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl- (9CI) (CA INDEX NAME)



IT 25322-68-3 25322-68-3D, Polyethylene glycol, ethers or
fatty acid esters
(particle-forming compns. containing fused pyrrolocarbazoles)
RN 25322-68-3 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



RN 25322-68-3 USPATFULL
CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



L17 ANSWER 7 OF 27 USPATFULL on STN
ACCESSION NUMBER: 2003:308310 USPATFULL Full-text
TITLE: Selected soluble esters of hydroxyl-containing
indolocarbazoles
INVENTOR(S): Mallamo, John P., Glenmore, PA, United States
Hudkins, Robert L., Chester Springs, PA, United States
PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S.
corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, JAPAN (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 38332	E1	20031125
	US 5686444		19971111 (Original)<--
APPLICATION INFO.:	US 2001-811725		20010319 (9)
	US 1996-624707		19960326 (Original)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1995-417611, filed on 5 Apr 1995, now patented, Pat. No. US 5650407		

DOCUMENT TYPE: Reissue
 FILE SEGMENT: GRANTED
 PRIMARY EXAMINER: Raymond, Richard L.
 LEGAL REPRESENTATIVE: Woodcock Washburn LLP
 NUMBER OF CLAIMS: 46
 EXEMPLARY CLAIM: 36
 NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
 LINE COUNT: 2111

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of hydroxyl-containing indolocarbazoles and acids containing selected solubilizing groups are provided. Compositions including the indolocarbazole esters and methods for the use of the indolocarbazole esters are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 156177-59-2

(preparation of)

RN 156177-59-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 183488-52-0P


(prepn.of soluble esters of hydroxyl-containing indolocarbazoles as choline acetyltransferase inhibitors)

RN 183488-52-0 USPTFULL

CN 3-Pyridinecarboxylic acid, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/718,077



IT 183488-46-2P 183488-48-4P 183488-50-3P
 183488-51-9P 183488-53-1P 183488-54-2P
 183488-56-4P 183488-58-6P 183488-60-0P
 183488-62-2P 183488-64-4P 183488-67-7P
 183488-70-2P


(prepn. of soluble esters of hydroxyl-containing indolocarbazoles as choline acetyltransferase inhibitors)

RN 183488-46-2 USPTFULL

CN L-Lysine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

10/718,077

RN 183488-48-4 USPTAFULL

CN Glycine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-50-8 USPTAFULL

CN L-Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-51-9 USPTAFULL

CN Butanedioic acid, mono[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 183488-53-1 USPTAFULL

CN Pyridinium, 3-[[[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methoxy]carbonyl]-1-methyl-, iodide (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 183488-54-2 USPTAFULL

CN Glycine, N,N-dimethyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 183488-56-4 USPATFULL
 CN Butanoic acid, 3-(dimethylamino)-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 183488-58-6 USPATFULL
 CN L-Histidine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-
 oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
 i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 183488-60-0 USPATFULL
 CN L-Arginine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 183488-62-2 USPTAFULL

CN β -Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-64-4 USPTAFULL

CN Alanine, 2-methyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-67-7 USPTAFULL

CN L-Glutamic acid, 1-[[[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl] ester, monohydrochloride (9CI) (CA INDEX NAME)

10/718,077

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 183488-70-2 USPATFULL

CN β -Alanine, L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



● 2 HCl


IT 183488-45-1P 183488-47-3P 183488-49-5P
 183488-57-5P 183488-59-7P 183488-61-1P
 183488-63-3P 183488-66-6P 183488-69-9P

(prepn. of soluble esters of hydroxyl-containing indolocarbazoles as choline acetyltransferase inhibitors)

RN 183488-45-1 USPATFULL

CN L-Lysine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-,
 [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-47-3 USPATFULL

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077





RN 183488-49-5 USPATFULL
 CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 183488-57-5 USPATFULL
 CN L-Histidine, N,1-bis[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 183488-59-7 USPATFULL
 CN L-Ornithine, N2-[(1,1-dimethylethoxy)carbonyl]-N5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 183488-61-1 USPATFULL

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-63-3 USPATFULL

CN Alanine, N-[(1,1-dimethylethoxy)carbonyl]-2-methyl-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-66-6 USPATFULL

CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 5-(1,1-dimethylethyl) 1-[(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl] ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-69-9 USPATFULL

CN β -Alanine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t

L17 ANSWER 8 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2002:239010 USPATFULL Full-text

TITLE: Remedies for ocular diseases

INVENTOR(S): Nakata, Katsuhiko, Sakurai, JAPAN

Kageyama, Masaaki, Neyagawa, JAPAN

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

Kyowa Hakko Kogyo Co., Ltd., JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451787	B1	20020917
	WO 2000021531		20000420
APPLICATION INFO.:	US 2001-807293		20010611 (9)
	WO 1999-JP5605		19991012
			20010611 PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1998-290194	19981013	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Kifle, Bruck		
LEGAL REPRESENTATIVE:	Woodcock Washburn LLP		
NUMBER OF CLAIMS:	7		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	396		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

10/718,077

AB Use of the compound represented by general formula (I) for remedies of and protection against eye diseases is disclosed. General formula (I): ##STR1##

(wherein, R^{sup.1} and R^{sup.2} independently represent a lower alkyl group, R^{sup.3} and R^{sup.4} independently represent a hydrogen atom or a lower alkyl group).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 156177-65-0 263554-49-0

(remedy for ocular diseases)

RN 156177-65-0 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 263554-49-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



L17 ANSWER 9 OF 27 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:178436 HCAPLUS [Full-text](#)
 DOCUMENT NUMBER: 134:227381
 TITLE: Particle-forming compositions containing fused
 pyrrolocarbazoles
 INVENTOR(S): Dickason, David A.; Patel, Piyush R.; Corvari,
 Vincent; Shek, Efraim; Herman, Joseph L.; Skell,
 Jeffry M.
 PATENT ASSIGNEE(S): Cephalon, Inc., USA
 SOURCE: U.S., 18 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6200968	B1	20010313	US 1999-368409	19990805
CA 2338546	A1	20000217	CA 1999-2338546	19990806 <--
EP 1102758	A1	20010530	EP 1999-940914	19990806 <--
EP 1102758	B1	20071017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
JP 2003524597	T	20030819	JP 2000-563637	19990806 <--
NZ 509596	A	20040730	NZ 1999-509596	19990806 <--
AT 375986	T	20071115	AT 1999-940914	19990806 <--
ES 2296401	T3	20080416	ES 1999-940914	19990806 <--
US 6660729	B1	20031209	US 2000-698901	20001027 <--
MX 2001PA01352	A	20020424	MX 2001-PA1352	20010206 <--
HK 1037622	A1	20080606	HK 2001-108404	20011129 <--
US 20040220176	A1	20041104	US 2003-718077	20031120 <--
PRIORITY APPLN. INFO.:			US 1998-95611P	P 19980806 <--
			US 1999-368409	A 19990805
			WO 1999-US17795	W 19990806
			US 2000-698901	A2 20001027

OTHER SOURCE(S): MARPAT 134:227381

AB A non-aqueous, particle-forming composition containing fused pyrrolocarbazole and a surfactant is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved

10/718,077

bioavailability of orally administered fused pyrrolocarbazole compds.
Pyrrolocarbazoles-containing compns. are useful for treatment of neurol.
disorders and cancer, especially prostate cancer, in mammals.

IT 118735-84-5 156177-72-9 156256-82-5
159404-60-1 173328-05-7 173328-06-8
173328-07-9 263554-49-0 329684-08-4
329684-15-3 329684-25-5 329684-26-6
329684-27-7 329684-30-2 329684-31-3
329684-32-4 329684-33-5 329684-34-6
329684-35-7 329684-37-9 329684-38-0
329684-39-1 329684-40-4


RL: BPR (Biological process); BSU (Biological study, unclassified); THU
(Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(preparation and therapeutic use of particle-forming compns. containing

fused

pyrrolocarbazoles with improved bioavailability)

RN 118735-84-5 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-
10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)




RN 156177-72-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic acid,
5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl
ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-82-5 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159404-60-1 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (CA INDEX NAME)

10/718,077



RN 173328-05-7 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 173328-06-8 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077



RN 173328-07-9 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[[(phenylamino)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 263554-49-0 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077



RN 329684-08-4 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl- (9CI) (CA INDEX NAME)




RN 329684-15-3 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)

10/718,077




RN 329684-25-5 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[(ethylamino) carbonyl] amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 329684-26-6 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester (9CI) (CA INDEX NAME)

10/718,077




RN 329684-27-7 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl
 ester (9CI) (CA INDEX NAME)




RN 329684-30-2 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-
 9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077




RN 329684-31-3 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-,
 methyl ester (9CI) (CA INDEX NAME)




RN 329684-32-4 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester
 (9CI) (CA INDEX NAME)

10/718,077



RN 329684-33-5 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 329684-34-6 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077



RN 329684-35-7 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)



RN 329684-37-9 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)

10/718,077



RN 329684-38-0 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 329684-39-1 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)


10/718,077



RN 329684-40-4 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 25322-68-3, Polyethylene glycol
 25322-68-3D, Polyethylene glycol, ethers and esters
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation and therapeutic use of particle-forming compns. containing fused pyrrolocarbazoles with improved bioavailability)
 RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



RN 25322-68-3 HCAPLUS

10/718,077

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 10 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2001:155765 USPATFULL Full-text

TITLE: Therapeutic and drug screening methods for the treatment and prevention of neuronal disease

INVENTOR(S): Robertson, George S., Ottawa, Canada
Korneluk, Robert G., Ottawa, Canada
MacKenzie, Alexander E., Ottawa, Canada
Xu, Daigen, Ottawa, Canada
Crocker, Stephen J., Halifax, Canada

PATENT ASSIGNEE(S): University of Ottawa, Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20010021699	A1	20010913
	US 6709866	B2	20040323
APPLICATION INFO.:	US 2001-735066	A1	20010220 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-844693, filed on 25 Apr 1997, GRANTED, Pat. No. US 6159948		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-30590P	19961114 (60)	<--
	US 1996-17354P	19960426 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Kristina Bieker-Brady, Ph.D., Clark & Elbing LLP, 176 Federal Street, Boston, MA, 02110		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Page(s)		
LINE COUNT:	2352		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99533-80-9, K252a


(NAIP (neuronal apoptotic inhibitory protein) and IAP polypeptides for neuronal disease treatment and prevention, and drug screening methods)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

10/718,077

Absolute stereochemistry. Rotation (+).



L17 ANSWER 11 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2001:18464 USPATFULL Full-text

TITLE: Use of K-252a derivative

INVENTOR(S): Engber, Thomas M, Berwyn, PA, United States
Haun, Forrest A., Wyncote, PA, United States
Saporito, Michael S., Westmont, NJ, United States
Aimone, Lisa D., Reading, PA, United States
Miller, Matthew S., Newtown, PA, United States
Knight, Jr., Ernest, Hilton Head Island, SC, United States
PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6184217	B1	20010206
APPLICATION INFO.:	US 1997-881679		19970624 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-20406P	19960625 (60) <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Goldberg, Jerome D.	
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris LLP	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	1010	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are therapeutic methodologies utilizing a ring substituted derivative of the indolocarbazole K-252a, the derivative represented by the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 156177-65-0

(K-252a derivative for treatment of peripheral or central nerve disorders and cytokine overprodn.)

10/718,077

RN 156177-65-0 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 12 OF 27 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:117036 HCAPLUS Full-text
 DOCUMENT NUMBER: 132:171117
 TITLE: Particle-forming compositions containing fused pyrrolocarbazoles
 INVENTOR(S): Dickason, David A.; Patel, Piyush R.; Corvari, Vincent; Shek, Efraim; Herman, Joseph L.; Skell, Jeffry M.
 PATENT ASSIGNEE(S): Cephalon, Inc., USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000008004	A1	20000217	WO 1999-US17795	19990806 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2338546	A1	20000217	CA 1999-2338546	19990806 <--
AU 9954674	A	20000228	AU 1999-54674	19990806 <--
AU 756865	B2	20030123		
EP 1102758	A1	20010530	EP 1999-940914	19990806 <--
EP 1102758	B1	20071017		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

10/718,077

IE, SI, LT, LV, FI, RO, CY				
JP 2003524597	T	20030819	JP 2000-563637	19990806 <--
NZ 509596	A	20040730	NZ 1999-509596	19990806 <--
MX 2001PA01352	A	20020424	MX 2001-PA1352	20010206 <--
HK 1037622	A1	20080606	HK 2001-108404	20011129 <--
PRIORITY APPLN. INFO.:			US 1998-95611P	P 19980806 <--
			US 1999-368409	A 19990805
			WO 1999-US17795	W 19990806


OTHER SOURCE(S): MARPAT 132:171117

AB A nonaq., particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides greatly improved bioavailability of orally administered fused pyrrolocarbazole compds. Thus, a formulation contained an indolocarbazole 100 mg/mL, PEG 1450 70 and Polysorbate 80 30%. The bioavailability of the drugs was improved significantly by the particle-forming composition

IT 258342-87-9 258342-88-0 258342-89-1
 RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (particle-forming compns. containing fused pyrrolocarbazoles)

RN 258342-87-9 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 258342-88-0 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)


10/718,077



RN 258342-89-1 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl- (9CI) (CA INDEX NAME)




IT 25322-68-3 25322-68-3D, Polyethylene glycol, ethers or fatty acid esters
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (particle-forming compns. containing fused pyrrolocarbazoles)
 RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



RN 25322-68-3 HCAPLUS
 CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)

10/718,077



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 13 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2000:167995 USPATFULL Full-text

TITLE: Therapeutic and drug screening methods for the treatment and prevention of neuronal disease

INVENTOR(S): Robertson, George S., Ottawa, Canada
Korneluk, Robert G., Ottawa, Canada
MacKenzie, Alexander E., Ottawa, Canada
Xu, Daigen, Ottawa, Canada
Crocker, Stephen J., Halifax, Canada

PATENT ASSIGNEE(S): University of Ottawa, Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6159948		20001212
APPLICATION INFO.:	US 1997-844693		19970425 (8)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-30590P	19961114 (60)	<--
	US 1996-17354P	19960426 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chambers, Jasemine		
ASSISTANT EXAMINER:	Baker, Anne-Marie		
LEGAL REPRESENTATIVE:	Clark & Elbing LLP, Bieker-Brady, Kristina		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	34 Drawing Figure(s); 34 Drawing Page(s)		
LINE COUNT:	2445		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB NAIP and IAP polypeptides prevent neuronal cell death caused by ischemia, neurodegenerative conditions, and axotomy. The invention provides methods for neuroprotection by the prevention of cell death and kits and methods for the identification of neuroprotective therapeutic compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9, K252a

(NAIP (neuronal apoptotic inhibitory protein) and IAP polypeptides for neuronal disease treatment and prevention, and drug screening methods)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L17 ANSWER 14 OF 27 USPATFULL on STN

ACCESSION NUMBER: 2000:109547 USPATFULL Full-text

TITLE: Detection and modulation of IAPS for the diagnosis and treatment of proliferative disease

INVENTOR(S): Korneluk, Robert G., Ontario, Canada
MacKenzie, Alexander E., Ontario, Canada

Liston, Peter, Ottawa, Canada

Baird, Stephen, Ottawa, Canada

Tsang, Benjamin K., Nepean, Canada

Pratt, Christine, Ontario, Canada

PATENT ASSIGNEE(S): Apoptogen, Inc., Ottawa, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6107041		20000822
APPLICATION INFO.:	US 1998-212971		19981216 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-800929, filed on 13 Feb 1997		

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1996-30590P	19961114 (60)	<--
	US 1996-17354P	19960426 (60)	<--

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Epps, Janets
LEGAL REPRESENTATIVE: Clark & Elbing LLP, Bieker-Brady, Kristina
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 42 Drawing Figure(s); 33 Drawing Page(s)
LINE COUNT: 3255

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids IAP fragments, and antibodies which specifically bind IAP polypeptides.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9, K252a

(NAIP (neuronal apoptotic inhibitory protein) and IAP polypeptides for neuronal disease treatment and prevention, and drug screening methods)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester,
(9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L17 ANSWER 15 OF 27 USPATFULL on STN

ACCESSION NUMBER: 1998:57918 USPATFULL Full-text

TITLE: Protein kinase inhibitors for treatment of neurological disorders

INVENTOR(S): Lewis, Michael E., West Chester, PA, United States
Kauer, James C., Kennett Square, PA, United States
Neff, Nicola, Wallingford, PA, United States
Roberts-Lewis, Jill, West Chester, PA, United States
Murakata, Chikara, Hachioji, Japan

Saito, Hiromitsu, Mishima, Japan

Matsuda, Yuzuru, Koganei, Japan

Glicksman, Marcie A., Swarthmore, PA, United States

Kanai, Fumihiko, Machida, Japan

Kaneko, Masami, Sagamihara, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

Kyowa Hakko Kogyo Co., Ltd., Japan (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5756494		19980526	<--
APPLICATION INFO.:	US 1995-456642		19950602	(8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-329540, filed on 26 Oct 1994 which is a continuation-in-part of Ser. No. US 1993-96561, filed on 22 Jul 1993, now patented, Pat. No. US 5461146 which is a continuation-in-part of Ser. No. US 1992-920102, filed on 24 Jul 1992, now abandoned			
DOCUMENT TYPE:	Utility			

FILE SEGMENT: Granted
 PRIMARY EXAMINER: Shah, Mukund J.
 ASSISTANT EXAMINER: Sripada, Pavanaram K.
 LEGAL REPRESENTATIVE: Fish & Richardson, P.C.
 NUMBER OF CLAIMS: 43
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 29 Drawing Figure(s); 22 Drawing Page(s)
 LINE COUNT: 3145

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99533-80-9P, K 252a 111358-88-4P 118735-80-1P

118735-94-7P 121664-75-3P 121664-76-4P
 121664-89-9P 121664-90-2P 121665-11-0P
 126643-38-7P 156177-59-2P 156177-61-6P
 156177-64-9P 156177-65-0P 156177-66-1P
 156177-72-9P 156177-73-0P 156177-74-1P
 156177-75-2P 156177-76-3P 156177-77-4P
 156177-79-6P 156256-82-5P 156256-84-7P
 156256-86-9P 167371-04-2P 167371-05-3P
 167371-06-4P 167371-07-5P 167371-08-6P
 167371-09-7P 167371-10-0P 167371-11-1P
 167371-12-2P 167371-13-3P 167371-14-4P
 167371-15-5P 167371-16-6P 167371-17-7P
 167371-18-8P 178404-41-6P 178404-44-9P
 178404-45-0P 178404-47-2P 178404-49-4P
 178404-51-8P 178404-52-9P 178404-53-0P
 178404-54-1P 178404-55-2P 178404-56-3P
 178404-63-2P 178404-64-3P 178404-65-4P
 178404-66-5P 178404-69-8P 178404-70-1P
 187811-05-8P 189822-46-6P


(preparation of staurosporine and K-252a derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/718,077



RN 111358-88-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-80-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-94-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-75-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylamino)carbonyl]amino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 121664-76-4 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121664-89-9 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-90-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 126643-38-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-propoxy-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-59-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-61-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-64-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-66-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-72-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-73-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-74-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-75-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-76-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-77-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-79-6 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156256-82-5 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156256-84-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156256-86-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-04-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-05-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-07-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-08-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-09-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(1H-benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-10-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[2-(benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-11-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1-pyrrolidinylimino)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-12-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylhydrazono)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-13-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-14-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1H-1,2,4-triazol-3-ylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-15-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(aminoiminomethyl)hydrazono]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-16-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[(4-morpholinylimino)methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-17-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylhydrazono)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-18-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[[4-methyl-1-piperazinyl]imino]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 178404-41-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(4H-1,2,4-triazol-4-ylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/718,077



RN 178404-44-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,16-bis(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-45-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—NMe₂

RN 178404-47-2 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 16-[[(2-aminoethyl)thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-49-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 14-[(ethylamino)carbonyl]amino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-51-8 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,14-diamino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-52-9 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-5,16-bis[(1-methylethyl)thio]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-53-0 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-5,16-bis[(propylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-54-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(butylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-55-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,16-bis(methoxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077




RN 178404-56-3 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-63-2 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-16-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-64-3 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[[(ethylamino) carbonyl] amino]-16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-65-4 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,9,16-trimethyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077




RN 178404-66-5 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[(ethylsulfinyl)methyl]-16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-69-8 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-2,3,9,10,11,12-hexahydro-9-methyl-5-nitro-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-70-1 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-5-[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187811-05-8 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 189822-46-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, hexyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 187810-82-8 208651-59-6

(preparation of staurosporine and K-252a derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 187810-82-8 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 208651-59-6 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-5,10-dihydroxy-16-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 178404-43-8P
 (staurosporine alkaloidal K 252a analogs as protein kinase inhibitors for treatment of neurol. disorders)
 RN 178404-43-8 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(butylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 16 OF 27 USPATFULL on STN

ACCESSION NUMBER: 1998:42376 USPATFULL Full-text

TITLE: Protein kinase inhibitors for treatment of neurological disorders

INVENTOR(S): Lewis, Michael E., West Chester, PA, United States
 Kauer, James C., Kennett Sq., PA, United States
 Neff, Nicola, Wallingford, PA, United States
 Roberts-Lewis, Jill, West Chester, PA, United States
 Murakata, Chikara, Hachioji, Japan
 Saito, Hiromitsu, Mishima, Japan
 Matsuda, Yuzuru, Koganei, Japan
 Glicksman, Marcie A., Swarthmore, PA, United States
 Kanai, Fumihiko, Machida, Japan
 Kaneko, Masami, Sagamihara, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
 Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5741808		19980421 <--
APPLICATION INFO.:	US 1997-800383		19970214 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-456642, filed on 2 Jun 1995 which is a continuation-in-part of Ser. No. US 1994-329540, filed on 26 Oct 1994, now patented, Pat. No. US 5621100 which is a continuation-in-part of Ser. No. US 1993-96561, filed on 22 Jul 1993, now patented, Pat. No. US 5461146 which is a continuation-in-part of Ser. No. US 1992-920102, filed on 24 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shaw, Mukund J.		
ASSISTANT EXAMINER:	Sripada, Pavanaram K.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	29 Drawing Figure(s); 22 Drawing Page(s)		
LINE COUNT:	2864		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			

AB The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 111358-88-4 118735-80-1 118735-94-7
 121664-75-3 121664-76-4 121664-89-9
 121665-11-0 156177-69-4 156177-72-9
 156177-73-0 156177-74-1 156177-75-2
 156177-76-3 156177-77-4 156177-79-6
 156177-80-9 156256-82-5 156256-84-7
 156256-86-9

(neuron function enhancing activity of)

RN 111358-88-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-80-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-94-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-75-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylamino)carbonyl]amino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-76-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-89-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-69-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylsulfinyl)methyl]-, methyl ester, (9 α ,10 β ,12 α)- (9CI) (CA INDEX NAME)


10/718,077



RN 156177-72-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-73-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-74-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-75-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-76-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-77-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-79-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(hydrazonomethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9 α ,10 β ,12 α)- (9CI) (CA INDEX NAME)


10/718,077



RN 156256-82-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156256-84-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-86-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156177-59-2P 156177-61-6P 156177-64-9P

156177-65-0P 156177-66-1P


(preparation of, for enhancing neuron function)

RN 156177-59-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-61-6 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-64-9 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-66-1 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 108043-96-5 121664-90-2 156177-72-9

(reaction of, in preparation of neuron function enhancing drug)

RN 108043-96-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9R,10S,12S)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121664-90-2 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156177-72-9 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L17 ANSWER 17 OF 27 HCAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 2
 ACCESSION NUMBER: 1997:124905 HCAPLUS Full-text
 DOCUMENT NUMBER: 126:216650
 ORIGINAL REFERENCE NO.: 126:41815a,41818a
 TITLE: Aqueous polyethylene glycol solutions containing indolocarbazoles
 INVENTOR(S): Goldstein, Joel D.; Herman, Joseph L.
 PATENT ASSIGNEE(S): Cephalon, Inc., USA
 SOURCE: U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 199,390, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

10/718,077

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5599808	A	19970204	US 1995-383414	19950203 <--
PRIORITY APPLN. INFO.:			US 1994-199390	B2 19940218 <--

GI



I


AB Solns. of indolocarbazoles, such as I [R = OH, OMe; R1 = H, Br, Cl, Me, NHCONHPh, CH2S(O)nEt, NMe2, NHCO2Me, CH2OCONHET, CH2OEt, CH2NMe2, CH2SEt, CH:NNH; R2 = H, Br, Cl, NHCONHET, CH2SEt, CH2OH; X = H, CH2N3, CO2Me, CH2OH, CONHET, CONH2, CONHPr, CH2S(O)Me, CH:NOH, CONHCH2CH2OH, CH:NNHCONH2, CH2OAc, CONHPh, CH2S(O)nPh; Z1 = Z2 = H; Z1Z2 = O; n = 0-2], contain 1-99% organic solvent, 0.25-10% dispersant, 0-99% H2O and 0-60% polyethylene glycol. Thus, K-252a was dissolved in a solvent containing 50% PEG-600, 2% benzyl alc., 10% Triton X-100 and 38% H2O to give a solution containing 10 mg/mL K-252a. Many I were also prepared

IT 25322-68-3

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of aqueous polyethylene glycol solns. containing indolocarbazoles)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




IT 118735-94-7 156177-72-9 167468-02-2
187810-82-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of aqueous polyethylene glycol solns. containing indolocarbazoles)

RN 118735-94-7 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-72-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167468-02-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, (9S,10S,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187810-82-8 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156177-59-2P 156177-61-6P 156177-64-9P
156177-65-0P 156177-66-1P 156177-75-2P
156177-76-3P 156177-77-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of aqueous polyethylene glycol solns. containing
indolocarbazoles)

RN 156177-59-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-61-6 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-64-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-66-1 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-75-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-76-3 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-77-4 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 99533-80-9DP, K 252a, derivs.

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aqueous polyethylene glycol solns. containing indolocarbazoles)

RN 99533-80-9 HCAPLUS


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 99533-80-9, K-252a 121664-90-2 187811-05-8
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preparation of aqueous polyethylene glycol solns. containing
 indolocarbazoles)
 RN 99533-80-9 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
 i][1,6]benzodiazocine-10-carboxylic acid,
 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester,
 (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 121664-90-2 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
 i][1,6]benzodiazocine-10-carboxylic acid,
 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-
 oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 187811-05-8 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester,
 (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 18 OF 27 USPATFULL on STN
 ACCESSION NUMBER: 97:104471 USPATFULL Full-text
 TITLE: Selected soluble esters of hydroxyl-containing
 indolocarbazoles
 INVENTOR(S): Mallamo, John P., Glenmore, PA, United States
 Hudkins, Robert L., Chester Springs, PA, United States
 PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S.
 corporation)
 Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S.
 corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5686444		19971111	<--
APPLICATION INFO.:	US 1996-624707		19960326	(8)

10/718,077

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-417611, filed on 5 Apr 1995
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Sripada, Pavanaram K.
LEGAL REPRESENTATIVE: Woodcock Washburn Kurtz MacKiewicz & Norris LLP
NUMBER OF CLAIMS: 35
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 15 Drawing Figure(s); 15 Drawing Page(s)
LINE COUNT: 1575

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of hydroxyl-containing indolocarbazoles and acids containing selected solubilizing groups are provided. Compositions including the indolocarbazole esters and methods for the use of the indolocarbazole esters are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 183488-52-0P 183488-62-2P


(preparation of soluble amino acid or dipeptide esters of hydroxyl-containing

indolocarbazoles)

RN 183488-52-0 USPTFULL

CN 3-Pyridinecarboxylic acid, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-62-2 USPTFULL

CN β -Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 183488-46-2P 183488-48-4P 183488-50-3P
 183488-51-9P 183488-54-2P 183488-56-4P
 183488-58-6P 183488-60-0P 183488-64-4P
 183488-67-7P 183488-70-2P 199280-49-4P
 199280-50-7P 199280-70-1P 199280-71-2P
 199280-72-3P 199280-73-4P 199280-74-5P
 199280-75-6P 199280-76-7P 199280-77-8P
 199280-78-9P 199280-79-0P 199280-80-3P

(preparation of soluble amino acid or dipeptide esters of hydroxyl-containing


indolocarbazoles)

RN 183488-46-2 USPTFULL

CN L-Lysine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




● 2 HCl

RN 183488-48-4 USPATFULL

CN Glycine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 183488-50-8 USPATFULL

CN L-Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 183488-51-9 USPATFULL

CN Butanedioic acid, mono[[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

10/718,077

i][1,6]benzodiazocin-10-yl)methyl] ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-54-2 USPATFULL

CN Glycine, N,N-dimethyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 183488-56-4 USPATFULL

CN Butanoic acid, 3-(dimethylamino)-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



RN 183488-58-6 USPATFULL
 CN L-Histidine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10/718,077

RN 183488-60-0 USPTAFULL
 CN L-Arginine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● 2 HCl

RN 183488-64-4 USPTAFULL
 CN Alanine, 2-methyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


10/718,077

RN 183488-67-7 USPTAFULL

CN L-Glutamic acid, 1-[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl] ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 183488-70-2 USPTAFULL

CN β -Alanine, L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 199280-49-4 USPATFULL

CN 3-Pyridinecarboxylic acid, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 199280-50-7 USPATFULL

CN 3-Pyridinecarboxylic acid, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]-, compd. with iodomethane (1:1) (9CI) (CA INDEX NAME)


10/718,077

CM 1

CRN 199280-49-4

CMF C33 H26 N4 O5

Absolute stereochemistry.



CM 2

CRN 74-88-4


CMF C H3 I

H₃C—I

RN 199280-70-1 USPATFULL

CN L-Lysine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/718,077

RN 199280-71-2 USPATFULL


CN Glycine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)



RN 199280-72-3 USPATFULL

CN L-Alanine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199280-73-4 USPATFULL

CN Glycine, N,N-dimethyl-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 199280-74-5 USPATFULL

CN Butanoic acid, 3-(dimethylamino)-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)




RN 199280-75-6 USPATFULL

CN L-Histidine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 199280-76-7 USPATFULL

CN L-Arginine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199280-77-8 USPATFULL

CN β -Alanine, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 199280-78-9 USPATFULL

CN Alanine, 2-methyl-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199280-79-0 USPATFULL

CN L-Glutamic acid, 1-[(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 199280-80-3 USPATFULL

CN β -Alanine, L-lysyl-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 156177-59-2

(preparation of soluble amino acid or dipeptide esters of hydroxyl-containing indolocarbazoles)

RN 156177-59-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 183488-45-1P 183488-47-3P 183488-49-5P
 183488-57-5P 183488-59-7P 183488-61-1P
 183488-63-3P 183488-66-6P 183488-69-9P

(preparation of soluble amino acid or dipeptide esters of hydroxyl-
 containing
 indolocarbazoles)

RN 183488-45-1 USPATFULL

CN L-Lysine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-,
 [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-
 epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-
 10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-47-3 USPATFULL

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

10/718,077





RN 183488-49-5 USPATFULL
 CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 183488-57-5 USPATFULL
 CN L-Histidine, N,1-bis[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 183488-59-7 USPATFULL
 CN L-Ornithine, N2-[(1,1-dimethylethoxy)carbonyl]-N5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 183488-61-1 USPATFULL

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-63-3 USPATFULL


CN Alanine, N-[(1,1-dimethylethoxy)carbonyl]-2-methyl-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 183488-66-6 USPATFULL
 CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 5-(1,1-dimethylethyl)
 1-[(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl] ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 183488-69-9 USPATFULL
 CN β -Alanine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-L-lysyl-,
 [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-
 epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-
 10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



— OBU-t

L17 ANSWER 19 OF 27 USPATFULL on STN
 ACCESSION NUMBER: 97:68592 USPATFULL Full-text
 TITLE: Indolocarbazole derivatives to treat a pathological condition of the prostate
 INVENTOR(S): Dionne, Craig A., Harleysville, PA, United States
 Contreras, Patricia C., West Chester, PA, United States
 Murakata, Chikara, Tokyo, Japan
 PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)
 Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5654427		19970805 <--
APPLICATION INFO.:	US 1995-463680		19950605 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1994-250175, filed on 27 May 1994, now patented, Pat. No. US 5516771 which is a continuation-in-part of Ser. No. US 1993-96622, filed on 22 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-69178, filed on 28 May 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1974		

10/718,077

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method of treating a pathological condition of the prostate gland, e.g., benign prostatic hypertrophy or prostate cancer, in a mammal, said method comprising administering to said mammal a therapeutic amount of the indolocarbazole compound K-252a or a preferred derivative thereof. The invention also includes novel derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 99533-80-9P 108043-96-5P 111358-88-4P
118735-80-1P 118735-93-6P 118735-94-7P
118736-02-0P 121664-75-3P 121664-76-4P
121664-89-9P 121664-90-2P 121665-11-0P
156177-59-2P 156177-76-3P 156256-84-7P
167370-94-7P 167371-02-0P 167371-03-1P
167371-04-2P 167371-05-3P 167371-06-4P
167371-07-5P 167371-08-6P 167371-09-7P
167371-10-0P 167371-11-1P 167371-12-2P
167371-13-3P 167371-14-4P 167371-15-5P
167371-16-6P 167371-17-7P 167371-18-8P


(claimed compound; preparation of indolocarbazole derivs. to treat prostatic

cancer and benign prostatic hypertrophy)

RN 99533-80-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 108043-96-5 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9R,10S,12S)- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/718,077



RN 111358-88-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 118735-80-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 118735-93-6 USPTAFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-chloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9 α ,10 β ,12 α)- (9CI) (CA INDEX NAME)



RN 118735-94-7 USPTAFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 118736-02-0 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, [9R-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121664-75-3 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 121664-76-4 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121664-89-9 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-90-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-59-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-76-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-84-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167370-94-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[2-[(ethylamino)oxy]-2-oxoethyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9 α ,10 β ,12 α)- (9CI) (CA INDEX NAME)


Currently available stereo shown.

10/718,077



RN 167371-02-0 USPATFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[bis(phenylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)



RN 167371-03-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-1,2,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


10/718,077



RN 167371-04-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-05-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-07-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-08-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-09-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(1H-benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-10-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[2-(benzofuran-2-ylmethyl)thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-11-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1-pyrrolidinylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-12-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylhydrazono)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-13-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-14-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1H-1,2,4-triazol-3-ylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-15-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(aminoiminomethyl)hydrazono]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-16-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[(4-morpholinylimino)methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-17-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylhydrazono)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/718,077



RN 167371-18-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[[4-methyl-1-piperazinyl]imino]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




IT 156177-65-0

(preparation of indolocarbazole derivs. to treat prostatic cancer and benign prostatic hypertrophy from)

RN 156177-65-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 167468-02-2P


(preparation of indolocarbazole derivs. to treat prostatic cancer and benign

prostatic hypertrophy from)

RN 167468-02-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 20 OF 27 USPTFULL on STN

ACCESSION NUMBER: 97:64006 USPTFULL [Full-text](#)

TITLE: Selected soluble esters of hydroxyl-containing indolocarbazoles

INVENTOR(S): Mallamo, John P., Glenmore, PA, United States
Hudkins, Robert L., Chester Springs, PA, United States

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

10/718,077

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5650407		19970722	<--
APPLICATION INFO.:	US 1995-417611		19950405	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Shah, Mukund J.			
ASSISTANT EXAMINER:	Sripada, Pavanaram K.			
LEGAL REPRESENTATIVE:	Woodcock Washburn Kurtz Mackiewicz & Norris			
NUMBER OF CLAIMS:	23			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	15 Drawing Figure(s); 15 Drawing Page(s)			
LINE COUNT:	1336			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Esters of hydroxyl-containing indolocarbazoles and acids containing selected solubilizing groups are provided. Compositions including the indolocarbazole esters and methods for the use of the indolocarbazole esters are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 156177-59-2

(preparation of)

RN 156177-59-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 183488-52-0F


(prepn.of soluble esters of hydroxyl-containing indolocarbazoles as choline acetyltransferase inhibitors)

RN 183488-52-0 USPTFULL

CN 3-Pyridinecarboxylic acid, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/718,077



IT 183488-46-2P 183488-48-4P 183488-50-3P
 183488-51-9P 183488-53-1P 183488-54-2P
 183488-56-4P 183488-58-6P 183488-60-0P
 183488-62-2P 183488-64-4P 183488-67-7P
 183488-70-2P


(prepn. of soluble esters of hydroxyl-containing indolocarbazoles as choline acetyltransferase inhibitors)

RN 183488-46-2 USPTFULL

CN L-Lysine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

10/718,077

RN 183488-48-4 USPTAFULL

CN Glycine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-50-8 USPTAFULL

CN L-Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-51-9 USPTAFULL

CN Butanedioic acid, mono[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 183488-53-1 USPTAFULL

CN Pyridinium, 3-[[[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methoxy]carbonyl]-1-methyl-, iodide (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 183488-54-2 USPTAFULL

CN Glycine, N,N-dimethyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 183488-56-4 USPATFULL
 CN Butanoic acid, 3-(dimethylamino)-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

● HCl

RN 183488-58-6 USPATFULL
 CN L-Histidine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-
 oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
 i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 183488-60-0 USPTFULL
 CN L-Arginine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 183488-62-2 USPTAFULL

CN β -Alanine, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-64-4 USPTAFULL

CN Alanine, 2-methyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183488-67-7 USPTAFULL

CN L-Glutamic acid, 1-[(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

10/718,077

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 183488-70-2 USPATFULL

CN β -Alanine, L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl]methyl ester, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



● 2 HCl

IT 183488-45-1P 183488-47-3P 183488-49-5P
 183488-57-5P 183488-59-7P 183488-61-1P
 183488-63-3P 183488-66-6P 183488-69-9P
 (prepn. of soluble esters of hydroxyl-containing indolocarbazoles as choline
 acetyltransferase inhibitors)
 RN 183488-45-1 USPATFULL
 CN L-Lysine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-,
 [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-
 epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-
 10-yl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-47-3 USPATFULL
 CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-,
 (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
 diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
 yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.


10/718,077



RN 183488-49-5 USPATFULL

CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)



Absolute stereochemistry.



RN 183488-57-5 USPATFULL

CN L-Histidine, N,1-bis[(1,1-dimethylethoxy)carbonyl]-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-59-7 USPATFULL
 CN L-Ornithine, N2-[(1,1-dimethylethoxy)carbonyl]-N5-[[[(1,1-dimethylethoxy)carbonyl]amino]iminomethyl]-, (2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 183488-61-1 USPATFULL

CN β -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-63-3 USPATFULL

CN Alanine, N-[(1,1-dimethylethoxy)carbonyl]-2-methyl-,
(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-
diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-
yl)methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 183488-66-6 USPATFULL

CN L-Glutamic acid, N-[(1,1-dimethylethoxy)carbonyl]-, 5-(1,1-dimethylethyl) 1-[(2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl] ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183488-69-9 USPATFULL

CN β -Alanine, N2,N6-bis[(1,1-dimethylethoxy)carbonyl]-L-lysyl-, [(9S,10S,12R)-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-10-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—OBu-t

L17 ANSWER 21 OF 27 USPATFULL on STN

ACCESSION NUMBER: 97:31819 USPATFULL Full-text

TITLE: Protein kinase inhibitors for treatment of neurological disorders

INVENTOR(S): Lewis, Michael E., West Chester, PA, United States
 Kauer, James C., Kennett Square, PA, United States
 Neff, Nicola, Wallingford, PA, United States
 Roberts-Lewis, Jill, West Chester, PA, United States
 Murakata, Chikara, Hachioji, Japan
 Saito, Hiromitsu, Mishima, Japan
 Matsuda, Yuzuru, Koganei, Japan
 Glicksman, Marcie A., Swarthmore, PA, United States
 Kanai, Fumihiko, Machida, Japan
 Kaneko, Masami, Sagamihara, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
 Kyowa Hakko Kogyo, Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5621101		19970415 <--
APPLICATION INFO.:	US 1995-486739		19950607 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1994-329540, filed on 26 Oct 1994, now patented, Pat. No. US 5621100 which is a continuation-in-part of Ser. No. US 1993-96561, filed on 22 Jul 1993, now patented, Pat. No. US 5461146 which is a continuation-in-part of Ser. No. US 1992-920102, filed on 24 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		

10/718,077

PRIMARY EXAMINER: Shah, Mukund J.
ASSISTANT EXAMINER: Sripada, Pavanaram K.
LEGAL REPRESENTATIVE: Fish & Richardson P.C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 27 Drawing Figure(s); 22 Drawing Page(s)
LINE COUNT: 2840

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 118735-94-7P 121664-89-9P 156177-72-9P

(preparation of K-252a derivs. as protein kinase inhibitors for treatment of
neuro. disorders)

RN 118735-94-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121664-89-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-72-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 99533-80-9DP, K-252a, derivs. 111358-88-4P

118735-80-1P 121664-75-3P 121664-76-4P
 121664-90-2P 121665-11-0P 126643-38-7P
 156177-59-2P 156177-61-6P 156177-64-9P
 156177-65-0P 156177-66-1P 156177-73-0P
 156177-74-1P 156177-75-2P 156177-76-3P
 156177-77-4P 156177-79-6P 156256-84-7P
 156256-86-9P 167371-04-2P 167371-05-3P
 167371-06-4P 167371-07-5P 167371-08-6P
 167371-09-7P 167371-10-0P 167371-11-1P
 167371-12-2P 167371-13-3P 167371-14-4P
 167371-15-5P 167371-16-6P 167371-17-7P
 167371-18-8P 178404-41-6P 178404-43-8P
 178404-45-0P 178404-47-2P 178404-49-4P
 178404-51-8P 178404-52-9P 178404-53-0P
 178404-54-1P 178404-55-2P 178404-56-3P

10/718,077


178404-63-2P 178404-64-3P 178404-65-4P
178404-66-5P 178404-68-7P 178404-69-8P
178404-70-1P 187811-05-8P 189822-46-6P
189827-88-1P

(preparation of K-252a derivs. as protein kinase inhibitors for treatment
of
neurological disorders)

RN 99533-80-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester,
(9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 111358-88-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-
(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 118735-80-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

10/718,077


i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester,
(9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 121664-75-3 USPTFULL
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic acid,
16-[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-
methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121664-76-4 USPTFULL
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-
i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-
[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-90-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 126643-38-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-propoxy-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-59-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-61-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-64-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-66-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 156177-73-0 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-74-1 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 156177-75-2 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-76-3 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-77-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-79-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-84-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156256-86-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-04-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-05-3 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-07-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-08-6 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-09-7 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(1H-benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-10-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[2-(benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-11-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1-pyrrolidinylimino)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-12-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylhydrazono)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-13-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-14-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1H-1,2,4-triazol-3-ylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-15-5 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(aminoiminomethyl)hydrazono]methyl-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-16-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[(4-morpholinylimino)methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-17-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylhydrazono)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-18-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[[4-methyl-1-piperazinyl]imino]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 178404-41-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(4H-1,2,4-triazol-4-ylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.

10/718,077




RN 178404-43-8 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(butylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-45-0 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




—NMe₂

RN 178404-47-2 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 16-[[(2-aminoethyl)thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-49-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 14-[(ethylamino)carbonyl]amino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-51-8 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,14-diamino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-52-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-5,16-bis[(1-methylethyl)thio]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-53-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-5,16-bis[(propylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-54-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(butylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-55-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,16-bis(methoxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-56-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-63-2 USPTAFULL


CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-16-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-64-3 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[[(ethylamino) carbonyl] amino]-16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-65-4 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,9,16-trimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-66-5 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5-[(ethylsulfinyl)methyl]-16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-68-7 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,10,16-tris(hydroxymethyl)-9-methyl-, [9S-(9α,10β,12α)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077




RN 178404-69-8 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-2,3,9,10,11,12-hexahydro-9-methyl-5-nitro-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 178404-70-1 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-5-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187811-05-8 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189822-46-6 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, hexyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 189827-88-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-, [9S-(9 α ,10 β ,12 α)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 187810-82-8

(preparation of K-252a derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 187810-82-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 178404-44-9P

(preparation of K-252a derivs. as protein kinase inhibitors for treatment of
of
neurological disorders)

RN 178404-44-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-hydroxy-5,16-bis(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 22 OF 27 USPTAFULL on STN

ACCESSION NUMBER: 97:31818 USPTAFULL [Full-text](#)

TITLE: K-252a derivatives for treatment of neurological disorders

INVENTOR(S): Lewis, Michael E., West Chester, PA, United States
Kauer, James C., Kennett Square, PA, United States
Neff, Nicola, Wallingford, PA, United States
Roberts-Lewis, Jill, West Chester, PA, United States
Murakata, Chikara, Hachioji, Japan
Saito, Hiromitsu, Mishima, Japan
Matsuda, Yuzuru, Koganei, Japan

10/718,077

PATENT ASSIGNEE(S): Glicksman, Marcie A., Swarthmore, PA, United States
Kanai, Fumihiko, Machida, Japan
Kaneko, Masami, Sagamihara, Japan
Cephalon, Inc., West Chester, PA, United States (U.S.
corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5621100		19970415 <--
APPLICATION INFO.:	US 1994-329540		19941026 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-96561, filed on 22 Jul 1993, now patented, Pat. No. US 5461146 which is a continuation-in-part of Ser. No. US 1992-920102, filed on 24 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shah, Mukund J.		
ASSISTANT EXAMINER:	Sripada, Pavanaram K.		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	1		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 20 Drawing Page(s)		
LINE COUNT:	2356		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. The invention also features a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 118735-94-7P 121664-89-9P 156177-72-9P
(preparation of K-252a derivs. as protein kinase inhibitors for treatment
of
neuro. disorders)

RN 118735-94-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl
ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121664-89-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-72-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 99533-80-9DP, K-252a, derivs. 111358-88-4P

118735-80-1P 121664-75-3P 121664-76-4P

121664-90-2P 121665-11-0P 126643-38-7P

156177-59-2P 156177-61-6P 156177-64-9P

156177-65-0P 156177-66-1P 156177-73-0P

156177-74-1P 156177-75-2P 156177-76-3P

156177-77-4P 156177-79-6P 156256-82-5P

156256--84--7P 156256--86--9P 167371--04--2P

167371-05-3P 167371-06-4P 167371-07-5P

167371--08--6P 167371--09--7P 167371--10--0P

167371-11-1P 167371-12-2P 167371-13-3P

167371-14-4P 167371-15-5P 167371-16-6P

167371-17-7P 167371-18-8P 178404-41-6P

178404-43--8P 178404-45--0P 178404-47--2P

178404-49-4P 178404-51-8P 187811-05-8P

189822-46-6P

```
(preparation of K-252a derivs. as protein kinase inhibitors for treatment
```

of


neurol. disorders)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


10/718,077



RN 111358-88-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 118735-80-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-75-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-76-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-90-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 126643-38-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-propoxy-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-59-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-61-6 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-64-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-66-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 156177-73-0 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-74-1 USPTFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 156177-75-2 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-76-3 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-77-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-79-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-82-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156256-84-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156256-86-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-04-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-05-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-07-5 USPATFULL

CN	9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)	
----	---	--

Absolute stereochemistry.




RN 167371-08-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/718,077




RN 167371-09-7 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(1H-benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167371-10-0 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(2-furanylmethyl)thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-11-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1-pyrrolidinylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-12-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylhydrazono)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/718,077



RN 167371-13-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-14-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1H-1,2,4-triazol-3-ylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-15-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[aminoiminomethyl]hydrazono]methyl-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-16-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[(4-morpholinylimino)methyl]-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/718,077



RN 167371-17-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylhydrazono)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-18-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[[4-methyl-1-piperazinyl]imino]methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.


10/718,077



RN 178404-41-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(4H-1,2,4-triazol-4-ylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 178404-43-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(butylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 178404-45-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



—NMe₂

RN 178404-47-2 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[(2-aminoethyl)thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 178404-49-4 USPATFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 14-[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 178404-51-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,14-diamino-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187811-05-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 189822-46-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, hexyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 187810-82-8

(preparation of K-252a derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 187810-82-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 178404-44-9P

(preparation of K-252a derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 178404-44-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-5,16-bis(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 23 OF 27 USPATFULL on STN

ACCESSION NUMBER: 96:41211 USPATFULL [Full-text](#)

TITLE: K-252 derivatives which enhance neurotrophin-induced activity

INVENTOR(S): Glicksman, Marcie A., Swarthmore, PA, United States
Hudkins, Robert L., Chester Springs, PA, United States
Rotella, David P., Dowington, PA, United States
Neff, Nicola T., Rose Valley, PA, United States
Murakata, Chikara, Tokyo, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)

10/718,077

Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5516772		19960514 <--
APPLICATION INFO.:	US 1994-307530		19940916 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-122893, filed on 16 Sep 1993, now patented, Pat. No. US 5468872		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Haley, Jacqueline		
LEGAL REPRESENTATIVE:	Fish & Richardson, Burgoon, Jr., Richard P.		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1241		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed are derivatives of the indolocarbazole alkaloid K-252a of the Formulae I-VI, useful for enhancing neurotrophin-induced activity of neurotrophin responsive cells. A particularly preferred neurotrophin is NT-3, and a particularly preferred neurotrophin responsive cell is one which comprises a trk receptor. The enhanced neurotrophin-induced activity occasioned by the disclosed K-252a derivatives may be determined by the following assays: ChAT activity; DRG neuronal survival; or cell division (mitogenesis).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9D, K-252a, derivs. 124911-38-2
124911-39-3

(K-252 derivs. for enhancement of neurotrophin-induced activity, measurement of activity enhancement, and derivative preparation)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 124911-38-2 USPATFULL


10/718,077

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 3-(ethylthio)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 124911-39-3 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-3,10-dihydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 167468-02-2

(K-252 derivs.for enhancement of neurotrophin-induced activity, measurement of activity enhancement, and derivative preparation)

RN 167468-02-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 24 OF 27 USPATFULL on STN

ACCESSION NUMBER: 96:41210 USPATFULL Full-text

TITLE: Use of indolocarbazole derivatives to treat a pathological condition of the prostate

INVENTOR(S): Dionne, Craig A., Harleysville, PA, United States
Contreras, Patricia C., West Chester, PA, United States
Murakata, Chikara, Tokyo, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5516771		19960514 <--
APPLICATION INFO.:	US 1994-250175		19940527 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-96622, filed on 22 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1993-69178, filed on 28 May 1993		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Raymond, Richard L.		
LEGAL REPRESENTATIVE:	Burgoon, Jr., Richard P. Fish & Richardson		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)		
LINE COUNT:	1997		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features a method of treating a pathological condition of the prostate gland, e.g., benign prostatic hypertrophy or prostate cancer, in a mammal, said method comprising administering to said mammal a therapeutic amount of the indolocarbazole compound K-252a or a preferred derivative thereof. The invention also includes novel derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 108043-96-5P 111358-88-4P 118735-80-1P
118735-94-7P 118736-02-0P 121664-75-3P
121664-76-4P 121665-11-0P 156177-59-2P
156177-66-1P 156177-72-9P 156177-74-1P

10/718,077


156177-75-2P 156177-76-3P 156177-77-4P
156256-82-5P 156256-84-7P 167371-04-2P
167371-05-3P 167371-06-4P 167371-07-5P
167371-08-6P 167371-09-7P 167371-10-0P
167371-11-1P 167371-12-2P 167371-13-3P
167371-14-4P 167371-15-5P 167371-16-6P
167371-17-7P 167371-18-8P 178247-69-3P

(use of indolocarbazole derivs. to treat pathol. condition of the prostate)

RN 108043-96-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester, (9R,10S,12S)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 111358-88-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.




10/718,077

RN 118735-80-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-94-7 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 118736-02-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, [9R-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/718,077



RN 121664-75-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-76-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121665-11-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-59-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)


Absolute stereochemistry.

10/718,077




RN 156177-66-1 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 156177-72-9 USPTAFULL
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-74-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-75-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-76-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-77-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-82-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156256-84-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-04-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-05-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[(4,5-dihydro-1H-imidazol-2-yl)hydrazono]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-07-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-08-6 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-09-7 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(1H-benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-10-0 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[2-(benzimidazol-2-ylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-11-1 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1-pyrrolidinylimino)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-12-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylhydrazono)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 167371-13-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[2-(dimethylamino)ethyl]thio]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-14-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(1H-1,2,4-triazol-3-ylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-15-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(aminoiminomethyl)hydrazono]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-16-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[(4-morpholinylimino)methyl]-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-17-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylhydrazono)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry unknown.



RN 167371-18-8 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-16-[[4-methyl-1-piperazinyl]imino]methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 178247-69-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, [9S-(9α,10β,12α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/718,077




IT 99533-80-9P, K-252a

(use of indolocarbazole derivs. to treat pathol. condition of the prostate)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT 167468-02-2

(use of indolocarbazole derivs. to treat pathol. condition of the prostate)

RN 167468-02-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 167371-02-0P 167371-03-1P

(use of indolocarbazole derivs. to treat pathol. condition of the prostate)


RN 167371-02-0 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[bis(phenylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)



RN 167371-03-1 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(1,3-dithiolan-2-yl)-1,2,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, [9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)



L17 ANSWER 25 OF 27 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1995:931389 HCAPLUS Full-text
 DOCUMENT NUMBER: 124:15478
 ORIGINAL REFERENCE NO.: 124:2921a,2924a
 TITLE: Aqueous indolocarbazole solutions
 INVENTOR(S): Goldstein, Joel D.; Herman, Joseph L.
 PATENT ASSIGNEE(S): Cephalon, Inc., USA
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9522331	A1	19950824	WO 1995-US1436	19950203 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9519110	A	19950904	AU 1995-19110	19950203 <--
PRIORITY APPLN. INFO.:			US 1994-199390	A 19940218 <--
			WO 1995-US1436	W 19950203 <--

OTHER SOURCE(S): MARPAT 124:15478


AB Indolocarbazole solns. are disclosed. The invention features a solution comprising: (i) an indolocarbazole; (ii) a selected organic solvent being present in a concentration of between about 1% and about 99% by weight inclusive, (iii) a dispersant being present in a concentration of between about 0.25% and about 10% by weight inclusive; (i.v.) water being present in a concentration of between 0% and about 99% by weight inclusive, and (v) a polyethylene glycol being present in a concentration of between 0% and about 60% by weight inclusive.

IT 25322-68-3

RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (aqueous indolocarbazole pharmaceutical solns.)

RN 25322-68-3 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)



IT 108043-96-5 118735-94-7 156177-77-4


167468-02-2 170719-62-7 170719-64-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(aqueous indolocarbazole pharmaceutical solns.)

RN 108043-96-5 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
2,3,9,10,11,12-hexahydro-10-methoxy-9-methyl-1-oxo-, methyl ester,
(9R,10S,12S)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 118735-94-7 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl
ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



10/718,077


RN 156177-77-4 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167468-02-2 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-10-[[[(4-methylphenyl)sulfonyl]oxy]methyl]-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170719-62-7 HCAPLUS
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9 α ,10 α ,12 α)- (9CI) (CA INDEX NAME)


10/718,077



RN 170719-64-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9 α ,10 α ,12 α)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 156177-64-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aqueous indolocarbazole pharmaceutical solns.)

RN 156177-64-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino) carbonyl] amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/718,077



IT 156177-61-6P 156177-65-0P 156177-66-1P


156177-75-2P 156177-76-3P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aqueous indolocarbazole pharmaceutical solns.)

RN 156177-61-6 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-65-0 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry.

10/718,077



RN 156177-66-1 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-75-2 HCAPLUS
 CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid,
 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-76-3 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 99533-80-9, K 252a 118736-02-0 121664-90-2
156177-59-2

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aqueous indolocarbazole pharmaceutical solns.)

RN 99533-80-9 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 118736-02-0 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10,16-dihydroxy-9-methyl-1-oxo-, methyl ester, [9R-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 121664-90-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-59-2 HCAPLUS

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.



L17 ANSWER 26 OF 27 USPATFULL on STN

ACCESSION NUMBER: 95:103634 USPATFULL Full-text

TITLE: K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders

INVENTOR(S): Glicksman, Marcie A., Swarthmore, PA, United States
Rotella, David P., Downingtown, PA, United States
Neff, Nicola, Rose Valley, PA, United States
Murakata, Chikara, Tokyo, Japan

PATENT ASSIGNEE(S): Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5468872		19951121 <--

10/718,077

APPLICATION INFO.: US 1993-122893 19930916 (8)
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Haley, Jacqueline
LEGAL REPRESENTATIVE: Burgoon, Jr., Richard P. Fish & Richardson
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 7 Drawing Page(s)
LINE COUNT: 984

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Functional K-252a derivatives are used to enhance trk phosphorylation and to potentiate the activity of neurotrophin-3 (NT-3). These compounds can be used to treat neurological disorders, alone or in combination with NT-3.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 124911-38-2 124911-39-3 124911-40-6

(preparation of K-252a derivs. which enhance neurotrophin-induced activity)


RN 124911-38-2 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 3-(ethylthio)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)




RN 124911-39-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-3,10-dihydroxy-9-methyl-1-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 124911-40-6 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-3,10-dihydroxy-10-(hydroxymethyl)-9-methyl- (9CI) (CA INDEX NAME)



L17 ANSWER 27 OF 27 USPTAFULL on STN

ACCESSION NUMBER: 95:95012 USPTAFULL [Full-text](#)

TITLE: Selected protein kinase inhibitors for the treatment of neurological disorders

INVENTOR(S): Lewis, Michael E., West Chester, PA, United States
Kauer, James C., Kennett Square, PA, United States
Neff, Nicola, Wallingford, PA, United States
Roberts-Lewis, Jill, West Chester, PA, United States
Murakata, Chikara, Hachioji, Japan
Saito, Hiromitsu, Mishima, Japan
Matsuda, Yuzuru, Koganei, Japan

PATENT ASSIGNEE(S): Glicksman, Marcie A., Swarthmore, PA, United States
Cephalon, Inc., West Chester, PA, United States (U.S. corporation)
Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan (non-U.S. corporation)

10/718,077

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5461146		19951024 <--
APPLICATION INFO.:	US 1993-96561		19930722 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-920102, filed on 24 Jul 1992, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Datlow, Philip I.		
LEGAL REPRESENTATIVE:	Fish & Richardson		
NUMBER OF CLAIMS:	4		
EXEMPLARY CLAIM:	1,2,3,4		
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 14 Drawing Page(s)		
LINE COUNT:	1425		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features novel derivatives of K-252a, as well as novel bis-N-substituted derivatives of staurosporine. Also, a method for treating diseased neuronal cells involving the administration of either the novel staurosporine derivatives or specified functional derivatives of K-252a.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 99533-80-9, k-252a 111358-88-4 118735-80-1
 118735-94-7 121664-75-3 121664-76-4
 121664-89-9 121665-11-0 156177-73-0
 156177-75-2 156177-76-3 156177-77-4
 156177-79-6 156256-82-5 156256-84-7
 156256-86-9 167371-04-2 167371-05-3
 167371-06-4 167371-07-5 167371-08-6
 173662-32-3

(preparation of staurosporine derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 99533-80-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 111358-88-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

10/718,077


i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 118735-80-1 USPATFULL
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9,16-dimethyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 118735-94-7 USPATFULL
CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-75-3 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 121664-76-4 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[[[(phenylamino)carbonyl]amino]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 121664-89-9 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 121665-11-0 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(ethoxymethyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-73-0 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(phenylthio)methyl]-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-75-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[[[(ethylamino)carbonyl]oxy]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-76-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-16-[(methoxycarbonyl)amino]-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156177-77-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dibromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-79-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(dimethylamino)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 156256-82-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 10-[(acetyloxy)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-, (9S,10S,12R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156256-84-7 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 16-bromo-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 156256-86-9 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-(dimethylamino)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 167371-04-2 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-05-3 USPTFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(4,5-dihydro-1H-imidazol-2-yl)hydrazone]methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.


10/718,077



RN 167371-06-4 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylthio)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167371-07-5 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyrimidinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 167371-08-6 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-16-[(2-pyridinylsulfinyl)methyl]-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173662-32-3 USPATFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 5,16-dichloro-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-,
[9S-(9 α ,10 β ,12 α)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 156177-61-6

(preparation of staurosporine derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 156177-61-6 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfonyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156177-64-9P 156177-65-9P 156177-66-1P


(preparation of staurosporine derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 156177-64-9 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[[(ethylamino)carbonyl]amino]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/718,077



RN 156177-65-0 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 156177-66-1 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-5-(hydroxymethyl)-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 121664-90-2

(preparation of staurosporine derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 121664-90-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 16-[(ethylsulfinyl)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 156177-59-2P


(preparation of staurosporine derivs. as protein kinase inhibitors for treatment of neurol. disorders)

RN 156177-59-2 USPTAFULL

CN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-1-one, 2,3,9,10,11,12-hexahydro-10-(hydroxymethyl)-10-methoxy-9-methyl-, (9S,10S,12R)- (CA INDEX NAME)

Absolute stereochemistry.

10/718,077



SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 16:22:01 ON 02 DEC 2008)

FILE 'HCAPLUS' ENTERED AT 16:22:31 ON 02 DEC 2008

E DICKASON DAVE/AU

L1 11 SEA ABB=ON ("DICKASON D"/AU OR "DICKASON DAVE"/AU OR "DICKASON DAVID A"/AU)

E MCINTYRE BRADLEY T/AU

L2 5 SEA ABB=ON "MCINTYRE BRADLEY T"/AU

E PATEL PIYUSH R/AU

L3 17 SEA ABB=ON ("PATEL PIYUSH R"/AU OR "PATEL PIYUSH RAMANBHAI"/AU OR "PATEL PIYUSH RANCHODBHAI"/AU OR "PATEL PIYUSH V"/AU)

L4 1 SEA ABB=ON L1 AND L2 AND L3
SELECT RN L4 1

FILE 'REGISTRY' ENTERED AT 16:23:43 ON 02 DEC 2008

L5 9 SEA ABB=ON (106392-12-5/BI OR 222414-51-9/BI OR 25322-68-3/BI OR 258342-87-9/BI OR 263554-49-0/BI OR 329684-08-4/BI OR 329684-15-3/BI OR 9002-96-4/BI OR 9004-99-3/BI)

FILE 'HCAPLUS' ENTERED AT 16:23:48 ON 02 DEC 2008

L6 1 SEA ABB=ON L4 AND L5

FILE 'REGISTRY' ENTERED AT 16:25:39 ON 02 DEC 2008

L7 STRUCTURE 329684-15-3

L8 35 SEA SSS SAM L7

L9 699 SEA SSS FUL L7

L10 1 SEA ABB=ON 329684-15-3/RN

FILE 'HCAPLUS' ENTERED AT 16:26:35 ON 02 DEC 2008

L11 660 SEA ABB=ON L9

FILE 'REGISTRY' ENTERED AT 16:26:53 ON 02 DEC 2008

E POLYOXYL STEARATE/CN

L12 1 SEA ABB=ON "POLYOXYL STEARATE"/CN

E POLYETHYLENE GLYCOL/CN

L13 1 SEA ABB=ON "POLYETHYLENE GLYCOL"/CN

FILE 'HCAPLUS' ENTERED AT 16:27:16 ON 02 DEC 2008

L14 12 SEA ABB=ON L11 AND (L12 OR ?POLYOXYL?(W)?STEARATE? OR L13 OR ?POLYETHYLENE?(W)?GLYCOL?)

L15 5 SEA ABB=ON L14 AND (PRD<19990508 OR PD<19990508)

FILE 'USPATFULL' ENTERED AT 16:28:16 ON 02 DEC 2008

L16 24 SEA ABB=ON L14 AND (PRD<19990508 OR PD<19990508)

FILE 'HCAPLUS, USPATFULL' ENTERED AT 16:28:30 ON 02 DEC 2008

L17 27 DUP REMOV L15 L16 (2 DUPLICATES REMOVED)

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

10/718,077

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2008 VOL 149 ISS 23
FILE LAST UPDATED: 1 Dec 2008 (20081201/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2
DICTIONARY FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Dec 2008 (20081202/PD)
FILE LAST UPDATED: 2 Dec 2008 (20081202/ED)
HIGHEST GRANTED PATENT NUMBER: US7461407
HIGHEST APPLICATION PUBLICATION NUMBER: US20080295209
CA INDEXING IS CURRENT THROUGH 2 Dec 2008 (20081202/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Dec 2008 (20081202/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.